Vitiligo is a common and a disfiguring autoimmune disease, which has a negative impact on patients' selfesteem and quality of life. Pathogenesis of Vitiligo involves the interaction between defects of natural and extrinsic melanocytes, immune innate to swelling and destruction of T-cell-mediated melanocyte. Vitiligo affects about 1% of the general population. The risk of the disease was 6% for siblings and 23% for identical twins treatment is not only intended to stop the disease, but also to support repigmentation through the regeneration, proliferation and migration of melanocytes. Treatment strategies for dealing with all aspects of pathogenesis and pigmentation can be very effective, and this strategy may require a combination. Current treatments generally do not imply objective autoimmunity, and emerging treatments may use more specific methods based on a deep understanding of the pathogenesis of the disease, which can provide a good safety profile with a higher effectiveness. However, as with most medical treatments, careful patient selection and monitoring should enable us to normalize the pathogenic response of vitiligo in order to achieve the internal balance of healthy individuals.
Introduction
Vitiligo is a common and disfiguring autoimmune disease, which has a negative impact on patients' selfesteem and quality of life [1, 2] . The current treatment [3] . Vitiligo is caused by a dynamic interaction between genetic and environmental risks, which can trigger an autoimmune attack on skin melanocytes.
Pathogenesis of vitiligo Genetics
The wider observation of vitiligo in the immediate relatives of patients with vitiligo provides early evidence for its heredity. Vitiligo affects about 1% of the general population [4] . The risk of the disease was 6% for siblings and 23% for identical twins [5] . In addition, vitiligo patients and their relatives are at increased risk of other autoimmune diseases, including autoimmune thyroiditis, type 1 diabetes mellitus, pernicious anemia and Addison's disease, suggesting that vitiligo is also an autoimmune disease [6] . These early observations were later confirmed by genomewide association (GWA) studies, which found that many common genetic variations in vitiligo patients encode congenital (NLRP1, IFIH1, casp7, c1qtnf6, trif) and adaptive immune system components (FOXP3, BACH2, CD80, CCR6, PTPN22, IL2R, alpha GZMB, HLA class I and II) [7] [8] [9] .
Oxidative Stress
There is increasing evidence that melanocytes in vitiligo patients have inherent defects, which reduce their ability to cope with cellular stress [10] . Epidermal cells, including melanocytes, are often exposed to environmental pressures, such as ultraviolet radiation and various chemicals, which can increase the production of reactive oxygen species (ROS). Although healthy melanocytes can relieve these stresses, melanocytes from patients with vitiligo seem to be more vulnerable. For example, melanocytes from the skin of peripheral vitiligo exhibit dilated endoplasmic reticulum (ER) and abnormal structure of mitochondria and melanosomes, which are characteristics of increased cellular stress. High concentrations of epidermal H2O2
and decreased level of catalase (a key enzyme that protects cells from oxidative damage) were observed in the skin of vitiligo patients [11] [12] [13] [14] [15] [16] [17] .
Environment
The earliest trigger for vitiligo is not entirely clear.
Several studies have shown that the combination of defects in melanocytes and exposure to specific environmental factors may play a central role in the pathogenesis of diseases. This is evident in a group of factory workers who developed vitiligo in gloves after exposure to a single benzophenone, an organic chemical [18] .
Later studies confirmed that the contact history of other phenolic and catecholic chemicals found in dyes (especially hair dyes), resins/adhesives and leather was related to vitiligo [19, 20] . Melanogenesis is a multistep process in which melanocytes produce melanin.
Tyrosinase is a rate-limiting enzyme in this process, which controls melanin production by oxidizing amino acid tyrosine (a natural phenol) [21] . In vitro studies have shown that chemical phenols can act as tyrosine analogues in melanocytes, leading to high levels of cellular stress. This may include increased production of reactive oxygen species (ROS) and activation of unfolded protein response (UPR), which in turn activates congenital inflammation [22, 23] . 
Innate Immunity

Emerging treatment
According to our current understanding of the pathogenesis of vitiligo, successful strategies for treating vitiligo should include three different approaches: reducing melanocyte stress, regulating autoimmune response and stimulating melanocyte regeneration. Existing therapies partly meet these needs, but emerging therapies may do so in a more targeted way, and combination therapies may produce better overall responses ( Figure 1 ). nbUVB compared with placebo [47] . A group of participants tested nbUVB with or without an "antioxidant pool" consisting of alpha-fatty acids, vitamin C, vitamin E and polyunsaturated fatty acids.
They report that nbUVB combined with antioxidants is more effective for patients [48] . Greater controlled trials are needed to determine whether antioxidants are beneficial for patient management.
Regulation of autoimmunity
In the past decade, immunomodulators have made significant progress in the treatment of inflammatory skin diseases, including targeted treatment. Our latest understanding of the immune pathogenesis of vitiligo helps us identify new immune targets and develop and test new treatment methods for vitiligo.
HSP70i -group reported the role of heat shock protein
HSP70i in the pathogenesis of vitiligo, suggesting that heat shock protein HSP70i is released by stress melanocytes and causes congenital inflammation in the skin [49] . Then they found that the mutant protein reduced its immunogenicity and even induced tolerance when expressed in the skin of a mouse model to prevent Ruxolitinib, another JAK inhibitor with JAK 1/2 selectivity, has been approved by FDA for the treatment of moderate or high risk myelofibrosis and polycythemia vera [52, 53] . We report a case of leukoplakia with rapid pigmentation of the face and trunk after oral administration of ruxolitinib [54] . The treatment response of these inhibitors does not seem to last long because the patient loses re-pigmentation after discontinuation of treatment [55] .
Like all other immunosuppressive drugs, tofacitinib and ruxotinib may have adverse effects, including opportunistic infections and rare malignant substances.
In addition, ruxotinib may income blood abnormalities including thrombocytopenia, anemia, and neutropenia [56] . Topical formulation of these drugs may provide therapeutic benefit without increasing the risk of adverse events [57] . Currently, an open label, phase 2, proof of concept clinical trial is recruiting participants to test the effectiveness of topical ruxotinib 1.5% in the treatment of vitiligo [58] .
In addition to JAK inhibitors, STAT inhibitors may have similar effects. So far, seven members of the family have been identified, but only STAT1 as a homodimer participates in IFN-gamma signal transduction [50] . A previous in vitro study reported that statins inhibited STAT1 function by inhibiting HMG-CoA reductase to reduce cholesterol [59] . In addition, a vitiligo patient was reported to have improved after taking simvastatin [60] . A recent study tested systemic simvastatin in a white spot mouse model and found that it was effective in preventing and reversing disease [61] . However, we conducted a small pilot clinical trial to test that the efficacy of high dose simvastatin (80 mg per day) in patients with generalized vitiligo did not reach its primary therapeutic end point molecules that regulate T cell responses to inflammation, including cytotoxic T lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), etc. [64] . Interestingly, the response of melanoma patients to immunoassay site inhibitors is associated with the development of vitiligo [65] . It has been hypothesized that activation of these surface receptors can restore tolerance in vitiligo patients [66] .
Abatacept is a fusion protein, which is composed of Fc 
Stimulation of melanocyte regeneration
α-MSH -Phototherapy is the first-line treatment for vitiligo, especially for patients with extensive diseases [1, 2] . Phototherapy and combined therapy. Although the mechanism of its therapeutic effect is not fully understood, photochromism may be due to its ability to induce immunosuppression. Melanocyte stem cells can also be induced to differentiate and proliferate [70] . In addition, the cream does not block potentially harmful ultraviolet light, so this method may not be as safe as nbUVB phototherapy.
Summary
In order to better understand the pathogenesis of vitiligo, studies have shown that an optimal treatment strategy should consider three key aspects of the 
